Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 known ✓ | Q9UBN7 | 3/20 | 0.76 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.59 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.59 |
| ▸ | GABRA1 known ✓ | P14867 | 3/20 | 0.58 |
| ▸ | GABRB2 known ✓ | P47870 | 3/20 | 0.58 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.58 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.58 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.56 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.56 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27627702 | 1.00 | HDAC6 (0.76) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| Hydrochloric Acid SCHEMBL27276199 | 0.99 | HDAC6 (0.74) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| SCHEMBL7040103 | 0.99 | HDAC6 (0.78) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| SCHEMBL11491143 | 0.89 | MAOB (0.65) | HDAC6HSD17B10CYP1A2KDM4EALDH1A1 | |
| SCHEMBL11491145 | 0.89 | MAOB (0.65) | HDAC6HSD17B10CYP1A2KDM4EALDH1A1 | |
| SCHEMBL28890661 | 0.86 | HDAC6 (1.00) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| Methylamine SCHEMBL15948925 | 0.86 | KDM4E (0.66) | HDAC6CYP1A2KDM4EALDH1A1MAOB | |
| SCHEMBL11469117 | 0.85 | HDAC6 (0.78) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| SCHEMBL11469118 | 0.85 | HDAC6 (0.78) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 | |
| SCHEMBL11437675 | 0.85 | HDAC6 (0.78) | HDAC6HSD17B10CYP1A2TRPV1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| CN-105377851-B | BET bromodomain inhibitors and therapeutic methods using these inhibitors | 密执安州立大学董事会 | 2018-07-20 | — | — | CN | disclosed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105377851-A | BET bromodomain inhibitors and therapeutic methods using these inhibitors | UNIV MICHIGAN REGENTS | 2016-03-02 | — | — | CN | disclosed |
| CN-102827082-B | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2015-01-07 | — | — | CN | disclosed |
| CN-101668769-B | Novel tetrahydrocarbazole derivatives as ligands of g-protein coupled receptors | AETERNA ZENTARIS GMBH | 2014-07-02 | — | — | CN | disclosed |
| CN-101448495-B | To M1Benzimidazole compound with active receptor and application thereof in medicines | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-102105473-B | Tricyclic nitrogen containing compounds and their use as antibacterials | GLAXO GROUP LTD | 2013-05-08 | — | — | CN | disclosed |
| CN-103058990-A | Benzimidazoles which have activity at m1 receptor and uses thereof in medicine | GLAXO GROUP LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-102827082-A | Thienopyrazole derivative having PDE7 inhibitory activity | DAIICHI SANKYO CO LTD | 2012-12-19 | — | — | CN | disclosed |
| CN-1832925-A | New p2x7 receptor avtagonists and their use | ASTRAZENECA AB (SE) | 2006-09-13 | — | — | CN | disclosed |
| CN-1655781-A | Novel heterocyclic compounds having beta-lactamase inhibitor activity | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| CN-1503684-A | Use of nk-1 receptor antagonists against benign prostatic hyperplasia | - | 2004-06-09 | — | — | CN | disclosed |
| CN-1103338-C | Heterocyclic compounds for treating myocardial ischaemia | PF MEDICAMENT (FR) | 2003-03-19 | — | — | CN | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| CN-1076022-C | Cyclic ether compounds as sodium channel modulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-12-12 | — | — | CN | disclosed |
| CN-1223652-A | Cyclic ether compounds as sodium channel modulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1999-07-21 | — | — | CN | disclosed |
| CN-1042335-C | 1-acylpiperidine compounds | NORVATIS AG (CH) | 1999-03-03 | — | — | CN | disclosed |
| CN-1193972-A | Heterocyclic compounds for treating myocardial ischaemia | PF MEDICAMENT (FR) | 1998-09-23 | — | — | CN | disclosed |
| CN-1089261-A | The 1-acylpiperidine compounds | CIBA GEIGY AG (CH) | 1994-07-13 | — | — | CN | disclosed |